Cheng H - Search Results

1

Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.

Cheng H, Borczuk A, Janakiram M, Ren X, Lin J, Assal A, Halmos B, Perez-Soler R, Zang X. Cheng H, et al. Clin Cancer Res. 2018 Apr 15;24(8):1954-1964. doi: 10.1158/1078-0432.CCR-17-2924. Epub 2018 Jan 26. Clin Cancer Res. 2018. PMID: 29374053 Free PMC article.

2

Glutathione metabolism in patients with non-small cell lung cancers.

Blair SL, Heerdt P, Sachar S, Abolhoda A, Hochwald S, Cheng H, Burt M. Blair SL, et al. Among authors: cheng h. Cancer Res. 1997 Jan 1;57(1):152-5. Cancer Res. 1997. PMID: 8988057

3

Molecular testing in lung cancer: the time is now.

Cheng H, Xu X, Costa DB, Powell CA, Halmos B. Cheng H, et al. Curr Oncol Rep. 2010 Sep;12(5):335-48. doi: 10.1007/s11912-010-0118-z. Curr Oncol Rep. 2010. PMID: 20623207 Review.

4

Thymidylate synthase expression and molecular alterations in adenosquamous carcinoma of the lung.

Shu C, Cheng H, Wang A, Mansukhani MM, Powell CA, Halmos B, Borczuk AC. Shu C, et al. Among authors: cheng h. Mod Pathol. 2013 Feb;26(2):239-46. doi: 10.1038/modpathol.2012.158. Epub 2012 Sep 21. Mod Pathol. 2013. PMID: 22996376 Free article.

5

PARP inhibition selectively increases sensitivity to cisplatin in ERCC1-low non-small cell lung cancer cells.

Cheng H, Zhang Z, Borczuk A, Powell CA, Balajee AS, Lieberman HB, Halmos B. Cheng H, et al. Carcinogenesis. 2013 Apr;34(4):739-49. doi: 10.1093/carcin/bgs393. Epub 2012 Dec 28. Carcinogenesis. 2013. PMID: 23275151 Free PMC article.

6

Cell cycle inhibitors for the treatment of NSCLC.

Shcherba M, Liang Y, Fernandes D, Perez-Soler R, Cheng H. Shcherba M, et al. Among authors: cheng h. Expert Opin Pharmacother. 2014 May;15(7):991-1004. doi: 10.1517/14656566.2014.902935. Epub 2014 Mar 25. Expert Opin Pharmacother. 2014. PMID: 24666387 Review.

7

Targeting the PI3K/AKT/mTOR pathway: potential for lung cancer treatment.

Cheng H, Shcherba M, Pendurti G, Liang Y, Piperdi B, Perez-Soler R. Cheng H, et al. Lung Cancer Manag. 2014 Jan 1;3(1):67-75. doi: 10.2217/lmt.13.72. Lung Cancer Manag. 2014. PMID: 25342981 Free PMC article.

8

Emerging drugs for squamous cell lung cancer.

Cheng H, Shcherba M, Kandavelou K, Liang Y, Liu H, Perez-Soler R. Cheng H, et al. Expert Opin Emerg Drugs. 2015 Mar;20(1):149-60. doi: 10.1517/14728214.2015.1001365. Epub 2015 Jan 5. Expert Opin Emerg Drugs. 2015. PMID: 25557559 Review.

9

Emerging treatment for advanced lung cancer with EGFR mutation.

Inal C, Yilmaz E, Piperdi B, Perez-Soler R, Cheng H. Inal C, et al. Among authors: cheng h. Expert Opin Emerg Drugs. 2015;20(4):597-612. doi: 10.1517/14728214.2015.1058778. Epub 2015 Jul 8. Expert Opin Emerg Drugs. 2015. PMID: 26153235 Review.

10

Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.

Liu X, Jia Y, Stoopler MB, Shen Y, Cheng H, Chen J, Mansukhani M, Koul S, Halmos B, Borczuk AC. Liu X, et al. Among authors: cheng h. J Clin Oncol. 2016 Mar 10;34(8):794-802. doi: 10.1200/JCO.2015.62.0674. Epub 2015 Jul 27. J Clin Oncol. 2016. PMID: 26215952

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

16,939 results

Search Page

Filters